Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.
Dorr DA, Burdon R, West DP, Lagman J, Georgopoulos C, Belknap SM, McKoy JM, Djulbegovic B, Edwards BJ, Weitzman SA, Boyle S, Tallman MS, Talpaz M, Sartor O, Bennett CL.
Dorr DA, et al. Among authors: djulbegovic b.
Clin Cancer Res. 2009 Jun 1;15(11):3850-5. doi: 10.1158/1078-0432.CCR-08-1811. Epub 2009 May 19.
Clin Cancer Res. 2009.
PMID: 19458059
Free PMC article.